Table 5.

COVID-19 Vaccines Oral Side Effects of Participating German Healthcare Workers, February–March 2021 (n = 599).

Variable	Outcome	mRNA Vaccine	Viral Vector Vaccine	Total	Sig.
Oral SE	Ulcers	8 (1.7%)	4 (3.2%)	12 (2%)	0.286 *
	Vesicles	22 (4.6%)	16 (12.8%)	38 (6.3%)	0.001 *
	Blisters	1 (0.2%)	1 (0.8%)	2 (0.3%)	0.374 *
	Angular Cheilitis	2 (0.4%)	1 (0.8%)	3 (0.5%)	0.505 *
	White/Red Plaque	3 (0.6%)	4 (3.2%)	7 (1.2%)	0.038 *
	Oral Paraesthesia	11 (2.3%)	2 (1.6%)	13 (2.2%)	1.000 *
	Taste Disturbance	4 (0.8%)	8 (6.4%)	12 (2%)	0.001 *
	Xerostomia	0 (0%)	3 (2.4%)	3 (0.5%)	0.009 *
	Halitosis	9 (1.9%)	13 (10.4%)	22 (3.7%)	<0.001 *
	Bleeding Gingiva	11 (2.3%)	15 (12%)	26 (4.3%)	<0.001
	Swollen Mucosa	8 (1.7%)	5 (4%)	13 (2.2%)	0.158 *
	Total	59 (12.4%)	47 (37.6%)	106 (17.7%)	<0.001
Oral SE Onset	1–3 days	29 (37.7%)	30 (60%)	59 (46.5%)	<0.001
	1st Week	25 (32.5%)	12 (24%)	37 (29.1%)	0.074
	2nd Week	12 (15.6%)	3 (6%)	15 (11.8%)	1.000 *
	3rd Week	6 (7.8%)	3 (6%)	9 (7.1%)	0.404 *
	4th Week	5 (6.5%)	2 (4%)	7 (5.5%)	0.640 *
Ulcers/Vesicles/Blisters Location	Tongue	5 (18.5%)	7 (41.2%)	12 (27.3%)	0.164 *
	Palate	8 (29.6%)	3 (17.6%)	11 (25%)	0.486 *
	Labial/Buccal Mucosa	10 (37%)	9 (52.9%)	19 (43.2%)	0.300
	Gingiva	2 (7.4%)	1 (5.9%)	3 (6.8%)	1.000 *
	Lips	9 (33.3%)	4 (23.5%)	13 (29.5%)	0.488
White/Red Plaque Location	Tongue Dorsum	1 (33.3%)	3 (75%)	4 (57.1%)	0.486 *
	Soft Palate	1 (33.3%)	2 (50%)	3 (42.9%)	1.000 *
	Labial/Buccal Mucosa	2 (66.7%)	2 (50%)	4 (57.1%)	1.000 *

Chi-squared test and Fisher’s exact test (*) were used with a significance level of <0.05.